Clinical trial
A Phase 1 / 2, Randomized, Double-Blind, Placebo-Controlled Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis
NCT03500263 is registered in ClinicalTrials.gov with Proteostasis Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 / 2, Randomized, Double-Blind, Placebo-Controlled Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis
- Lead sponsor
- Proteostasis Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 30, 2018
- Completion date
- March 13, 2019
- Enrollment
- 12 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.